Edition:
United Kingdom

Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta


Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA.PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY. 

Related Company News

Company Quote

91.3
0.22 +0.24%
4:35pm BST